State Street Corp Reata Pharmaceuticals Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $6.35 Million - $8.45 Million	80,205 Added 12.67%	713,150 $72.7 Million
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $1.61 Million - $4.85 Million	-52,047 Reduced 7.6%	632,945 $57.5 Million
Q4 2022 Feb 14, 2023	SELL	$22.15 - $42.11 $1.47 Million - $2.79 Million	-66,251 Reduced 8.82%	684,992 $26 Million
Q3 2022 Nov 15, 2022	BUY	$19.41 - $36.49 $184,977 - $347,749	9,530 Added 1.28%	751,243 $18.9 Million
Q2 2022 Aug 15, 2022	BUY	$20.71 - $36.5 $1.53 Million - $2.69 Million	73,695 Added 11.03%	741,713 $22.5 Million
Q1 2022 May 16, 2022	SELL	$24.12 - $39.6 $14,375 - $23,601	-596 Reduced 0.09%	668,018 $21.9 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $1.14 Million - $4.96 Million	44,658 Added 7.16%	668,614 $17.6 Million
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $3.45 Million - $4.93 Million	34,467 Added 5.85%	623,956 $62.8 Million
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $16.4 Million - $31.6 Million	209,100 Added 54.97%	589,489 $83.4 Million
Q1 2021 May 17, 2021	SELL	$94.25 - $132.81 $270,497 - $381,164	-2,870 Reduced 0.75%	380,389 $37.9 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $410,466 - $742,726	-4,023 Reduced 1.04%	383,259 $47.4 Million
Q3 2020 Nov 10, 2020	BUY	$93.53 - $163.34 $2.43 Million - $4.25 Million	26,005 Added 7.2%	387,282 $37.7 Million
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $19.8 Million - $27.7 Million	-156,888 Reduced 30.28%	361,277 $56.4 Million
Q1 2020 May 11, 2020	BUY	$124.16 - $247.74 $64.3 Million - $128 Million	518,165 New	518,165 $74.8 Million

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account